Previous 10 | Next 10 |
Vaccinex (NASDAQ: VCNX ): Q1 GAAP EPS of -$0.45 beats by $0.30 . More news on: Vaccinex, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Approaching key topline data in non-small cell lung cancer and Huntington’s disease Advancing plans to expand pepinemab development to include Alzheimer’s disease ROCHESTER, N.Y., May 14, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotech...
ROCHESTER, N.Y., May 13, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced a poster presentation highlighting ...
Every solution to every problem is simple. It's the distance between the two where the mystery lies . - Derek Landy Today, we take an in-depth look at a ‘ Tier 4 ’ biotech concern located in upstate New York. The concern posted some updated trial results this morning that ...
Thinly traded nano cap Vaccinex ( VCNX +9.8% ) is up more than an 8x surge in volume, albeit on turnover of only 289K shares, on the heels of updated data from a Phase 1b/2 clinical trial, CLASSICAL-Lung , evaluating pepinemab, combined with Pfizer ( PFE +1.5% ) and Merck KGaA's ( OTC...
Vaccinex (NASDAQ: VCNX ) presents updated interim results from CLASSICAL-Lung, the Phase 1b/2 study of pepinemab in combination with anti-PD-L1 checkpoint inhibitor avelumab (BAVENCIO) in non-small cell lung cancer (NSCLC), at the American Association for Cancer Research. More news on: V...
ROCHESTER, N.Y., April 27, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D), today announced the presentation ...
ROCHESTER, N.Y., April 07, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and neurodegenerative diseases, today announced that the company’s vice president of preclinical res...
Kiniksa Pharmaceuticals (NASDAQ: KNSA ) announces "early evidence" of treatment response in COVID-19-related pneumonia and hyperinflammation with antibody mavrilimumab. Shares up 42% premarket. More news on: Kiniksa Pharmaceuticals, Ltd., Vaccinex, Inc., BioCorRx Inc., Health...
ROCHESTER, N.Y., March 31, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and neurodegenerative diseases, today announced that the company has entered into two agreements that combi...
News, Short Squeeze, Breakout and More Instantly...
Company expects to lock database in June and remains on track to report key outcomes later in July. Pepinemab targets astrocyte reactivity and neuroinflammation, believed to be key drivers of neurodegeneration. ROCHESTER, N.Y., June 06, 2024 (GLOBE NEWSWIRE) -- Vaccinex, I...
A look at the top 10 most actives in the United States Novo Integrated Sciences Inc. (NVOS) rose 132.8% to $1.05 on volume of 308,155,573 shares Greenwave Technology Solutions Inc. (GWAV) fell 7.9% to $0.0387 on volume of 278,348,616 shares Faraday Future Intelligent Electric Inc. (FFIE) ...
Vaccinex, Inc. (NASDAQ: VCNX) is one of today's top gainers. The company's shares have moved 15.16% on the day to $6. Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet...